Trails Edge Capital Partners LP Buys New Stake in CAMP4 Therapeutics Corporation $CAMP

Key Points

• Trails Edge Capital Partners LP acquired 1.93 million CAMP shares during the second quarter, valued at approximately $8.45 million and representing 3.08% of the company. Several other institutional investors also initiated or increased positions.
• Analysts maintain a generally positive outlook, with seven Buy ratings, one Hold, and one Sell; the stock has a “Moderate Buy” consensus rating and an average price target of $9.56.
• CAMP opened at $4.45 and remains well below its 52-week high of $7.75. The company reported a quarterly loss of $0.58 per share versus the expected $0.24 loss, with revenue of $1.78 million.

Trails Edge Capital Partners LP bought a new stake in CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,932,937 shares of the Wireless communications provider's stock, valued at approximately $8,446,935,000. CAMP4 Therapeutics accounts for approximately 1.3% of Trails Edge Capital Partners LP's investment portfolio, making the stock its 27th biggest holding. Trails Edge Capital Partners LP owned 3.08% of CAMP4 Therapeutics as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at $27,581,000. 5AM Venture Management LLC purchased a new position in CAMP4 Therapeutics during the 2nd quarter valued at about $25,647,928,000. Vivo Capital LLC purchased a new position in CAMP4 Therapeutics during the 3rd quarter valued at about $11,765,000. Balyasny Asset Management L.P. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at about $14,938,000. Finally, Janus Henderson Group PLC grew its position in CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock valued at $38,807,000 after acquiring an additional 1,666,666 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CAMP. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 10th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Piper Sandler reiterated an "overweight" rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and raised their price target for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $9.56.

CAMP4 Therapeutics Price Performance

CAMP stock opened at $4.45 on Wednesday. The business's 50-day moving average is $4.13 and its two-hundred day moving average is $4.35. The firm has a market capitalization of $279.24 million, a P/E ratio of -1.92 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million for the quarter. On average, analysts expect that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Andrew J. Schwab sold 114,700 shares of CAMP4 Therapeutics stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the transaction, the director owned 2,465,298 shares in the company, valued at $11,192,452.92. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard A. Young purchased 16,378 shares of the stock in a transaction on Monday, August 3rd. The shares were purchased at an average price of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director directly owned 186,388 shares in the company, valued at $307,540.20. This represents a 9.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 36,031 shares of company stock valued at $59,451 and sold 193,603 shares valued at $887,992. 21.69% of the stock is owned by insiders.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

Want to see what other hedge funds are holding CAMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source